The BioPharm Brief: RNA Editing, Cardiac Remodeling, Rare Disease Gene TherapyByEmily SchoenthalerJune 3rd 2026
The BioPharm Brief: Gene Therapy Reform, Cancer Trial Endpoints, and a $1.2B Rare Disease DealByEmily SchoenthalerJune 2nd 2026
The BioPharm Brief: Smarter Immunotherapy, Stronger Responses, Longer SurvivalByEmily SchoenthalerJune 1st 2026